EH
CN
Home
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Contact Us
EH
CN
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Our Science
Clinical Trial
Platform
Partnership
Investor
Stock Information
Investor Hotline
Home
>
Investor
Stock Information
Investor Hotline
Investor
002653
Haisco
RMB
海思科:关于控股股东部分股份质押的公告
海思科:关于控股股东部分股份质押及质押展期的公告
海思科:关于获得创新药注射用HSK36273临床试验申请《受理通知书》的公告
海思科:关于《专利实施许可协议及相关协议之解除协议》交易进展的公告
海思科:关于收到《中国证监会行政许可项目审查二次反馈意见通知书》的公告
海思科:关于控股股东部分股份质押及解除质押的公告
海思科:关于2021年限制性股票激励计划授予完成的公告
海思科:关于获得创新药环泊酚注射液《药品注册证书》的公告